ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Could a patent dispute over Celgene MS hopeful ozanimod tank the BMS deal?
March 15, 2019As if Bristol-Myers Squibb didn’t have enough to worry about, what with major investors trying to scuttle its $74 billion acquisition of Celgene, now a new concern has emerged—and it involves one of the six drug candidates that BMS executives have cited a
Pharma Sources Insight January 2025
